
|Videos|October 19, 2015
Optimizing the Specialty Drug Pathway from Manufacturers to Pharmacies
Author(s)Davy James, Managing Editor
Cheryl Allen, RPh, BSPharm, MBA, vice president of Industry Relations at Diplomat, discusses how relationships can be improved between manufacturers, pharmacy benefit managers, and pharmacies.
Advertisement
Cheryl Allen, RPh, BSPharm, MBA, vice president of Industry Relations at Diplomat, discusses how relationships can be improved between manufacturers, pharmacy benefit managers, and pharmacies.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Implementing Enfortumab Vedotin-ejfv Plus Pembrolizumab: Navigating Safety Data and the Pharmacist’s Role
2
Key Data, Interviews at the 2025 ASH Annual Meeting and Exposition
3
Long-Term BENEFIT Data Affirm Isa-VRd as Standard of Care in Transplant-Ineligible NDMM
4
Improving Outcomes in Diffuse B-Cell Lymphoma Requires Multidisciplinary Evolution
5

















































































































































































































